BREAST CANCER AND THE BIRTH CONTROL PILL

乳腺癌和避孕药

• 批准号: 2315157
• 负责人: LINDA SMITH
• 金额: $ 3.17万
• 依托单位: BARBARA ANN KARMANOS CANCER INSTITUTE
• 依托单位国家: 美国
• 财政年份: 1992
• 资助国家: 美国
• 起止时间: 1992-11-30 至 1999-11-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2315157
• 关键词: BREAST; CANCER; BIRTH; CONTROL; PILL

The primary objective of this contract is to provide for the conduct of an epidemiologic study of the risk of breast cancer among women, ages 35- 64, in relation to oral contraceptive use. Five Fields Centers shall participate in the conduct of a multi-center, population-based, concurrent case-control study to elucidate effects of: 1) current and lifetime OC use; 2) timing of OC use relative to other reproductive events; 3) differential effects of contraceptive estrogens and progestins; and 4) possible modification of OC effects by subsequent estrogen or hormone replacement therapy on the risk of breast cancer. A sufficient number of breast cancer cases and controls shall be enlisted to provide for the detection of a small overall relative risk of breast cancer (approximately a 20% increase or decrease) in oral contraceptive users compared to non-users. In addition, the sample size shall be large enough to provide for subgroup analyses, based on possible differences in risk that may exist for various subgroups. Subgroups shall be defined in terms of race, family history of breast cancer, parity and other reproductive characteristics of women, and other suspected breast cancer risk factors. A secondary objective of this contract is to examine biological differences between cases, which may be associated with exogenous hormone use.

该合同的主要目的是规定 一项关于女性乳腺癌风险的流行病学研究，年龄35-- 64，与口服避孕方法有关。 五个田地中心应 参加多中心，基于人群的行为 并发病例对照研究以阐明：1）电流和 终身OC使用； 2）OC的时机相对于其他生殖 事件； 3）避孕雌激素和 孕激素； 4）可能通过随后的方式修改OC效应 关于乳腺癌风险的雌激素或激素替代疗法。 应入伍足够数量的乳腺癌病例和对照 为检测乳房的总体相对风险很小 口服避孕药的癌症（大约增加或减少20％） 用户与非用户相比。 此外，样本量应大 足以根据可能的差异提供亚组分析 各种子组可能存在的风险。 亚组应定义 在种族，乳腺癌家族史，平等和其他方面 女性的生殖特征和其他疑似乳腺癌 风险因素。 该合同的次要目标是检查生物学 病例之间的差异，这可能与外源激素有关 使用。